PT Millennium Pharmacon International Tbk (SDPC.JK)
IDR 129.0
(-0.77%)
IDR 129.0
(-0.77%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 184.42 Billion IDR | -5.79% |
| 2022 | 185.25 Billion IDR | 7.13% |
| 2021 | 172.92 Billion IDR | 2.98% |
| 2020 | 167.91 Billion IDR | 2.72% |
| 2019 | 163.47 Billion IDR | 11.33% |
| 2018 | 146.83 Billion IDR | 13.14% |
| 2017 | 129.77 Billion IDR | 6.94% |
| 2016 | 121.36 Billion IDR | 5.66% |
| 2015 | 114.85 Billion IDR | 17.25% |
| 2014 | 97.96 Billion IDR | 9.72% |
| 2013 | 89.28 Billion IDR | 11.14% |
| 2012 | 80.33 Billion IDR | 14.38% |
| 2011 | 70.24 Billion IDR | 4.44% |
| 2010 | 67.25 Billion IDR | 3.67% |
| 2009 | 64.87 Billion IDR | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q3 | 50.49 Billion IDR | 2.63% |
| 2024 Q2 | 49.2 Billion IDR | -11.03% |
| 2024 Q1 | 55.3 Billion IDR | 23.07% |
| 2023 Q1 | 46.37 Billion IDR | -8.69% |
| 2023 FY | 174.52 Billion IDR | -5.79% |
| 2023 Q4 | 44.93 Billion IDR | -10.17% |
| 2023 Q3 | 50.02 Billion IDR | 54.28% |
| 2023 Q2 | 32.42 Billion IDR | -30.08% |
| 2022 Q3 | 44.51 Billion IDR | -3.06% |
| 2022 Q4 | 50.79 Billion IDR | 14.09% |
| 2022 Q1 | 44.01 Billion IDR | 16.75% |
| 2022 FY | 185.25 Billion IDR | 7.13% |
| 2022 Q2 | 45.92 Billion IDR | 4.35% |
| 2021 Q2 | 45.83 Billion IDR | 5.03% |
| 2021 FY | 172.92 Billion IDR | 2.98% |
| 2021 Q4 | 37.69 Billion IDR | -17.6% |
| 2021 Q3 | 45.74 Billion IDR | -0.19% |
| 2021 Q1 | 43.63 Billion IDR | -4.51% |
| 2020 FY | 167.91 Billion IDR | 2.72% |
| 2020 Q4 | 45.69 Billion IDR | 12.31% |
| 2020 Q1 | 44.12 Billion IDR | 3.52% |
| 2020 Q2 | 37.4 Billion IDR | -15.23% |
| 2020 Q3 | 40.68 Billion IDR | 8.78% |
| 2019 Q2 | 39.62 Billion IDR | -0.43% |
| 2019 FY | 163.47 Billion IDR | 11.33% |
| 2019 Q1 | 39.79 Billion IDR | 4.38% |
| 2019 Q4 | 42.62 Billion IDR | 2.88% |
| 2019 Q3 | 41.43 Billion IDR | 4.56% |
| 2018 Q3 | 37.56 Billion IDR | 4.65% |
| 2018 FY | 146.83 Billion IDR | 13.14% |
| 2018 Q1 | 35.23 Billion IDR | 17.18% |
| 2018 Q2 | 35.9 Billion IDR | 1.89% |
| 2018 Q4 | 38.12 Billion IDR | 1.48% |
| 2017 FY | 129.77 Billion IDR | 6.94% |
| 2017 Q1 | 32.64 Billion IDR | 9.28% |
| 2017 Q2 | 32.46 Billion IDR | -0.55% |
| 2017 Q3 | 34.59 Billion IDR | 6.57% |
| 2017 Q4 | 30.06 Billion IDR | -13.09% |
| 2016 Q1 | 31.07 Billion IDR | -6.97% |
| 2016 FY | 121.36 Billion IDR | 5.66% |
| 2016 Q4 | 29.87 Billion IDR | -4.75% |
| 2016 Q3 | 31.36 Billion IDR | 7.97% |
| 2016 Q2 | 29.04 Billion IDR | -6.52% |
| 2015 Q2 | 27.58 Billion IDR | 0.91% |
| 2015 Q1 | 27.33 Billion IDR | 8.64% |
| 2015 FY | 114.85 Billion IDR | 17.25% |
| 2015 Q4 | 33.4 Billion IDR | 25.86% |
| 2015 Q3 | 26.53 Billion IDR | -3.79% |
| 2014 Q1 | 22.77 Billion IDR | -3.06% |
| 2014 FY | 97.96 Billion IDR | 9.72% |
| 2014 Q3 | 24.58 Billion IDR | -3.36% |
| 2014 Q2 | 25.44 Billion IDR | 11.7% |
| 2014 Q4 | 25.15 Billion IDR | 2.33% |
| 2013 Q3 | 22.74 Billion IDR | 1.32% |
| 2013 Q2 | 22.44 Billion IDR | 1.08% |
| 2013 Q4 | 23.49 Billion IDR | 3.3% |
| 2013 FY | 89.28 Billion IDR | 11.14% |
| 2013 Q1 | 22.2 Billion IDR | 8.83% |
| 2012 FY | 80.33 Billion IDR | 14.38% |
| 2012 Q3 | 20.66 Billion IDR | 0.0% |
| 2012 Q4 | 20.4 Billion IDR | -1.27% |
| 2011 FY | 70.24 Billion IDR | 4.44% |
| 2010 FY | 67.25 Billion IDR | 3.67% |
| 2009 FY | 64.87 Billion IDR | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| PT Enseval Putera Megatrading Tbk. | 1992.05 Billion IDR | 90.742% |
| PT Itama Ranoraya Tbk | 100.18 Billion IDR | -84.078% |
| PT Kimia Farma (Persero) Tbk | 4350.51 Billion IDR | 95.761% |
| PT Soho Global Health Tbk | 851.38 Billion IDR | 78.339% |